title: Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement.
abstract: Recently published data show an extremely poor survival of infants with AML and HLXB9/ETV6 rearrangement which is the fusion, resulting from the translocation t(7;12)(q36;p13). None of the patients reported survived a period of 3 years, including four patients who have received allogeneic hematopoietic stem cell transplantation (HSCT). Herein, we report the clinical course of an 8-month-old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement. The patient received a haploidentical HSCT in relapse situation without any prior re-induction. The patient became MRD-negative over a period of 53 days after HSCT. This case reinforces the potential benefit of a graft-versus-leukemia effect in the haploidentical setting even in chemoresistant myeloid leukemias with poor-prognosis molecular features.
authors.affiliation: Pediatric Hematology & Oncology, LMU Munich, Dr. von Haunersches Children's Hospital, Munich, Germany. Julia.Hauer@med.uni-muenchen.de
authors.forename: Julia
authors.initials: J
authors.lastname: Hauer
authors.forename: Sabrina
authors.initials: S
authors.lastname: Tosi
authors.forename: Friedhelm R
authors.initials: FR
authors.lastname: Schuster
authors.forename: Jochen
authors.initials: J
authors.lastname: Harbott
authors.forename: Hans-Jochem
authors.initials: HJ
authors.lastname: Kolb
authors.forename: Arndt
authors.initials: A
authors.lastname: Borkhardt
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D005260:Female; D020544:Graft vs Leukemia Effect; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation; D018398:Homeodomain Proteins / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D050783:Proto-Oncogene Proteins c-ets / Q000235:genetics*; D012097:Repressor Proteins / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014157:Transcription Factors / Q000235:genetics*; D014178:Translocation, Genetic; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D018398:Homeodomain Proteins; D015514:Oncogene Proteins, Fusion; D050783:Proto-Oncogene Proteins c-ets; D012097:Repressor Proteins; D014157:Transcription Factors; D000097764:ETS Translocation Variant 6 Protein; C490003:MNX1 protein, human